CN117866905B - Stem cell based on nanobody gene modification and preparation method and product thereof - Google Patents
Stem cell based on nanobody gene modification and preparation method and product thereof Download PDFInfo
- Publication number
- CN117866905B CN117866905B CN202410276793.3A CN202410276793A CN117866905B CN 117866905 B CN117866905 B CN 117866905B CN 202410276793 A CN202410276793 A CN 202410276793A CN 117866905 B CN117866905 B CN 117866905B
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- stem cell
- nucleic acid
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 91
- 238000002360 preparation method Methods 0.000 title abstract description 17
- 238000012239 gene modification Methods 0.000 title abstract description 6
- 102000013691 Interleukin-17 Human genes 0.000 claims abstract description 78
- 108050003558 Interleukin-17 Proteins 0.000 claims abstract description 78
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 46
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 46
- 150000007523 nucleic acids Chemical class 0.000 claims description 37
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 238000001514 detection method Methods 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 24
- 238000004113 cell culture Methods 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 102000037865 fusion proteins Human genes 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000001890 transfection Methods 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 238000010362 genome editing Methods 0.000 claims description 3
- 238000001638 lipofection Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims 4
- 230000003248 secreting effect Effects 0.000 claims 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 abstract description 29
- 230000027455 binding Effects 0.000 abstract description 29
- 230000000903 blocking effect Effects 0.000 abstract description 21
- 238000011282 treatment Methods 0.000 abstract description 20
- 230000014509 gene expression Effects 0.000 abstract description 17
- 108091007433 antigens Proteins 0.000 abstract description 15
- 102000036639 antigens Human genes 0.000 abstract description 15
- 239000000427 antigen Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 77
- 102000004169 proteins and genes Human genes 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 33
- 235000001014 amino acid Nutrition 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 25
- 229960005435 ixekizumab Drugs 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 18
- 102100035018 Interleukin-17 receptor A Human genes 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 102000053602 DNA Human genes 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 15
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 12
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 11
- 210000002683 foot Anatomy 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 101710186083 Interleukin-17 receptor A Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 9
- 241000713666 Lentivirus Species 0.000 description 9
- 229920000057 Mannan Polymers 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- -1 glidants Substances 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101001019598 Homo sapiens Interleukin-17 receptor A Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 241001416177 Vicugna pacos Species 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 102000013264 Interleukin-23 Human genes 0.000 description 5
- 108010065637 Interleukin-23 Proteins 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 210000004504 adult stem cell Anatomy 0.000 description 5
- 238000007664 blowing Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 102000053162 human IL17A Human genes 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000009168 stem cell therapy Methods 0.000 description 4
- 238000009580 stem-cell therapy Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000012096 transfection reagent Substances 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
- 102100033461 Interleukin-17A Human genes 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 208000026872 Addison Disease Diseases 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000039989 IL-17 family Human genes 0.000 description 2
- 108091069193 IL-17 family Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102100035012 Interleukin-17 receptor C Human genes 0.000 description 2
- 101710186068 Interleukin-17 receptor C Proteins 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 208000005777 Lupus Nephritis Diseases 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000007584 Prealbumin Human genes 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000002818 protein evolution Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010048628 rheumatoid vasculitis Diseases 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- 101150040471 19 gene Proteins 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- 101150103244 ACT1 gene Proteins 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000023345 Autoimmune Diseases of the Nervous System Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101800005309 Carboxy-terminal peptide Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012441 Dermatitis bullous Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101000960235 Dictyostelium discoideum Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 101710140859 E3 ubiquitin ligase TRAF3IP2 Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010053177 Epidermolysis Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 description 1
- 108010017525 Interleukin-17 Receptors Proteins 0.000 description 1
- 102000004554 Interleukin-17 Receptors Human genes 0.000 description 1
- 102100033096 Interleukin-17D Human genes 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical group C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Chemical group CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 208000012309 Linear IgA disease Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010061269 Malignant peritoneal neoplasm Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010036697 Primary hypothyroidism Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010062164 Seronegative arthritis Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- RUXQWZJWMCHCHH-IZZDOVSWSA-N [(e)-1-pyridin-2-ylethylideneamino]urea Chemical compound NC(=O)N\N=C(/C)C1=CC=CC=N1 RUXQWZJWMCHCHH-IZZDOVSWSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003452 antibody preparation method Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000035362 autoimmune disorder of the nervous system Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 206010003883 azoospermia Diseases 0.000 description 1
- 238000013142 basic testing Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003508 chemical denaturation Methods 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 201000010918 connective tissue cancer Diseases 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 210000004489 deciduous teeth Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229930182817 methionine Chemical group 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 238000011296 nano differential scanning fluorimetry Methods 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 206010061311 nervous system neoplasm Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 201000002524 peritoneal carcinoma Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Dermatology (AREA)
- General Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
Abstract
The invention provides a stem cell based on nanobody gene modification, a preparation method and a product thereof, belonging to the technical field of stem cells. The stem cell based on nano antibody gene modification comprises, expresses or secretes a first antibody and a second antibody, wherein the first antibody comprises HCDR1, HCDR2 and HCDR3 with sequences shown as SEQ ID NO. 1-3; the second antibody comprises HCDR4, HCDR5 and HCDR6 with sequences shown in SEQ ID NO. 4-6. Compared with a single-domain antibody before tandem, the tandem antibody based on the stem cell expression modified by the nano antibody gene has better IL-17A antigen binding capacity and blocking activity, better stability compared with the single-domain antibody before tandem, and better disease treatment effect compared with a positive antibody. The serial nano antibody provided by the invention can be used for modifying stem cells, especially MSC, and has good clinical application prospect.
Description
Technical Field
The invention belongs to the technical field of stem cells, and particularly relates to a stem cell based on nano antibody gene modification, a preparation method and a product thereof.
Background
Stem cells are immature cells that are not sufficiently differentiated to have the potential to regenerate various tissues and organs and the human body. Stem cell therapy has been attempted in various diseases such as diabetes, parkinsonism, lupus erythematosus, leukemia, and the like. The preparation technology and application of induced pluripotent stem cells (induced pluripotent stem cell, iPSC) bring stem cell therapy into a brand new era. With the continued development of molecular biology techniques, particularly gene editing techniques, genetic modification has played an increasingly important role in stem cell therapy.
Stem cell therapy is a regenerative medicine technology, which aims to replace abnormal cells with cells having specific functions, restore the functions of the corresponding cells and improve the health state of the body. There are a variety of stem cells currently in clinical use, where HSC transplantation has improved prognosis for a variety of immune and blood system diseases, such as congenital immunodeficiency, multiple myeloma, thalassemia, and the like. Research data show that the implantation of allogeneic HSC can improve the 4-year survival rate of r/rAML (IDH 1/IDH2 mutated acute myelogenous leukemia) patients to 20% -35%. In addition, MSC has a certain immunoregulatory function, and thus is used for treating immune diseases, such as graft versus host disease, and the like, and achieves a certain curative effect. Autologous HSC drugs STRIMVELIS for the treatment of adenosine deaminase deficiency severe combined immunodeficiency disease (ADA-SCID) and autologous MSC drugs AstroStem for the treatment of alzheimer's disease have been disclosed in the prior art.
Mesenchymal stem cells (MESENCHYMAL STEM CELL, MSC) are multipotent stem cells, which are multipotent cells with self-replicating capacity. Under certain conditions, it can differentiate into a variety of functional cells like APSC pluripotent cells. Derived from mesoderm during embryonic development. MSCs are an important cell bank involved in tissue regeneration during normal tissue injury repair in the body. Under the action of special signals caused by tissue injury, MSC migrate to the injured part, locally accumulate and proliferate, and differentiate along different paths according to different injury signals. MSC is easy to separate and amplify, has vigorous in vitro multiplication capacity, and can maintain the multi-directional differentiation capacity even if amplified by 1 hundred million times. Therefore, MSC is a practical seed cell for tissue repair.
IL-17 is a key cytokine for protecting mucosal infection in hosts, and is also a major pathogenic cytokine and drug target for a variety of autoimmune and inflammatory diseases. The IL-17 family includes six members: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F, each of which mediates its biological functions through the IL-17 receptor (IL-17 RA to IL-17 RE). Among the most studied IL-17 family members is IL-17A, which promotes its biological activity by binding to IL-17RA and IL-17 RC. The prior art has disclosed that the study of the pathological role of IL-17A in human diseases has ultimately led to the development of monoclonal antibodies (mAbs) directed against IL-17A (IL-17A and IL-17F, IL-17RA or IL-23).
The prior art for studying the mode of action of IL-17 with stem cells is, for example, the China patent application with publication No. CN105079792A, which discloses the application of IL-17 in improving the immunosuppressive function of mesenchymal stem cells. In particular to the application of interleukin-17, interleukin-17 derivative or an agonist thereof in preparation of a preparation or a kit for improving the immunosuppressive function of mesenchymal stem cells; upregulating expression of immunosuppressive factors in mesenchymal stem cells; enhancing the stability of the mRNA of the immunosuppressive factor; reducing the expression level of the RNA binding protein AUF 1; inhibit proliferation of T cells; treating hepatitis or liver injury.
However, the prior art does not disclose the modification of stem cells by IL-17 related antibodies, in particular the role of IL-17A specific tandem antibodies in stem cell modification.
The present inventors have focused on anti-IL-17A antibody development and, for ease of examination, now briefly introduced the technical background of the development project:
The inventors have further developed techniques based on the 9 single domain antibodies screened (filed in the alternative), resulting in a combination of 12 single domain antibodies with relatively improved affinity, blocking effect and stability (filed in the alternative).
Based on the technical scheme, the invention continues to develop the technology of combining single-domain antibodies and genetically modified stem cells, and based on the relevant regulations of the singleness of the patent law, a plurality of different genetically modified stem cells are respectively claimed for protection.
For ease of understanding the invention, reference is optionally made to other patent application documents of this project.
Disclosure of Invention
In order to solve the problems, the invention provides a modified stem cell, which is screened based on immune alpaca to obtain a plurality of nano antibodies with IL-17A specific binding capacity, and two of the nano antibodies are selected to be connected in series so as to realize stem cell modification to prepare the genetically modified stem cell.
Stem cells of the invention, expression and/or secretion:
(1) A first antibody comprising a single domain antibody that specifically recognizes IL-17A; and
(2) A second antibody comprising a single domain antibody that specifically recognizes IL-17A;
the amino acid sequences of the first antibody and the second antibody are different.
The first antibody comprises HCDR1, HCDR2 and HCDR3 with sequences shown as SEQ ID NO. 1-3; and/or; an amino acid sequence having at least 80% sequence identity to the amino acid sequence set forth in SEQ ID NO. 1-3;
SEQ ID NO: 1:GEKLDYFA;
SEQ ID NO: 2:VTSSGSST;
SEQ ID NO: 3:ASTILLCSDYISAFGT。
The second antibody comprises HCDR4, HCDR5 and HCDR6 with the sequences shown in SEQ ID NO.4-6; and/or; an amino acid sequence having at least 80% sequence identity to the amino acid sequence set forth in SEQ ID NO.4-6;
SEQ ID NO: 4:GFSIHIYA;
SEQ ID NO: 5:ITRGGVT;
SEQ ID NO: 6:NAGGTNGGY。
Those skilled in the art know that CDR regions are regions of antibodies specifically recognizing antigens and have major binding activity, and thus, those skilled in the art can theoretically design various antibodies or fusion proteins for use according to the CDR regions described in the present invention. Such as in the form of nanobodies.
Alternatively, the first and second antibodies are linked directly or through a linker, preferably through a linker.
Preferably, the first antibody and the second antibody are linked by a linker, the linker is (GGGGS) n, and n is an integer not less than 1, more preferably 3.
Preferably, the stem cells comprise, express and/or secrete:
(1) A first protein, the structure of said first protein comprising:
FR1-HCDR1-FR2-HCDR2-FR3-HCDR3-FR4;
(2) A second protein, the structure of said second protein comprising:
FR5-HCDR4-FR6-HCDR5-FR7-HCDR6-FR8;
HCDR1-6 is selected from the amino acid sequences shown in SEQ ID NO 1-6; or; amino acid sequences having a difference of 1,2, 3, 4 or 5 amino acids compared to SEQ ID NO. 1-6;
FR1-8 is selected from the amino acid sequences shown in SEQ ID NO. 7-14; or; amino acid sequences having a difference of 1,2, 3, 4 or 5 amino acids compared to SEQ ID NO. 7-14.
SEQ ID NO:7:QVQLVESGGGLVQPGGSLRLSCAAS;
SEQ ID NO:8:IGWFRQAPGKEREVVSC;
SEQ ID NO:9:NYLSSVKDRFTISIDNAKNTVYLQMNSLKPEDTAIYYC;
SEQ ID NO:10:WGQGTQVTVAS;
SEQ ID NO:11:EVQLVESGGGLVQPGGSLRLSCAAS;
SEQ ID NO:12:MGWYRQAPGKQRELVAT;
SEQ ID NO:13:NNADSVKGRFTISRDNAKNTAYLQMNSLKPEDTAVYYC;
SEQ ID NO:14:WGQGTQVTVSS。
In the present invention, the amino acid difference may be achieved by at least one of addition, deletion, modification and/or substitution of an amino acid.
In some embodiments, the amino acid substitution is a conservative substitution, which is preferably a substitution of one amino acid in the following groups (a) to (e) with another amino acid residue in the same group: (a) small aliphatic, non-polar or weakly polar residues: ala, ser, thr, pro and Gly; (b) Polar, negatively charged residues and (uncharged) amides: asp, asn, glu and Gln; (c) polar, positively charged residues: his, arg and Lys; (d) large aliphatic, nonpolar residues: met, leu, he, val and Cys; and (e) an aromatic residue: phe, tyr and Trp.
In some preferred embodiments, conservative substitutions are as follows: ala to Gly or to Ser; arg to Lys; asn to Gln or to His; asp to Glu; cys to Ser; gln to Asn; glu to Asp; gly to Ala or to Pro; his to Asn or to Gln; lie to Leu or to Val; leu to Ile or to Val; lys to Arg, to gin, or to Glu; met to Leu, to Tyr or to Ile; phe to Met, to Leu, or to Tyr; ser to Thr; thr to Ser; trp to Tyr; tyr to Trp; and/or Phe to Val, to Ile or to Leu.
Further preferred, said stem cells comprise, express and/or secrete fusion proteins;
The fusion protein comprises an amino acid sequence with the structure of FR1-HCDR1-FR2-HCDR2-FR3-HCDR3-FR4-linker-FR5-HCDR4-FR6-HCDR5-FR7-HCDR6-FR 8;
HCDR1-6 is selected from: amino acid sequences shown in SEQ ID NO. 1-6; or; amino acid sequences having a difference of 1,2, 3,4 or 5 amino acids compared to SEQ ID NO. 1-6;
FR1-8 is selected from the group consisting of: amino acid sequence shown in SEQ ID NO. 7-14; or; amino acid sequence having a difference of 1,2, 3,4 or 5 amino acids compared to SEQ ID NO. 7-14;
the linker is selected from: the amino acid sequence shown in SEQ ID NO. 15.
SEQ ID NO: 15:GGGGSGGGGSGGGGS。
Still further preferred, said stem cells comprise, express and/or secrete:
(1) A first protein, wherein the sequence of the first protein comprises an amino acid sequence shown as SEQ ID NO. 16;
(2) And the second protein comprises an amino acid sequence shown as SEQ ID NO. 17.
SEQ ID NO:16:
QVQLVESGGGLVQPGGSLRLSCAASGEKLDYFAIGWFRQAPGKEREVVSCVTSSGSSTNYLSSVKDRFTISIDNAKNTVYLQMNSLKPEDTAIYYCASTILLCSDYISAFGTWGQGTQVTVAS.
SEQ ID NO:17:
EVQLVESGGGLVQPGGSLRLSCAASGFSIHIYAMGWYRQAPGKQRELVATITRGGVTNNADSVKGRFTISRDNAKNTAYLQMNSLKPEDTAVYYCNAGGTNGGYWGQGTQVTVSS.
In some embodiments, presented as examples, the stem cells comprise, express and/or secrete fusion proteins:
The sequence of the fusion protein comprises: SEQ ID NO. 16-SEQ ID NO. 15-SEQ ID NO. 17-SEQ ID NO. 26.
SEQ ID NO: 26:
APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK.
Based on the above, it will be appreciated by those skilled in the art that the present invention provides a stem cell comprising:
(1) A first nucleic acid molecule; and; (2) a second nucleic acid molecule;
the first nucleic acid molecule codes for a nucleotide sequence comprising the amino acid sequence shown in SEQ ID NO. 1-3;
The first nucleic acid molecule encodes a nucleotide sequence comprising the amino acid sequence shown in SEQ ID NO. 4-6.
The first nucleic acid molecule codes for a nucleotide sequence comprising the amino acid sequence shown in SEQ ID NO. 7-10;
the first nucleic acid molecule encodes a nucleotide sequence comprising the amino acid sequence shown in SEQ ID NO. 11-14.
Preferably, the first nucleic acid molecule and the second nucleic acid molecule are linked by a nucleotide sequence encoding an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO. 15.
Further preferably, the stem cell comprises:
(1) A first nucleic acid molecule; and; (2) a second nucleic acid molecule;
The first nucleic acid molecule codes for a nucleotide sequence comprising the amino acid sequence shown in SEQ ID NO. 16;
the first nucleic acid molecule encodes a nucleotide sequence comprising the amino acid sequence shown in SEQ ID NO. 17.
In some specific embodiments, the stem cells described by way of example comprise: nucleotide sequence encoding the amino acid sequence represented by SEQ ID NO. 16-SEQ ID NO. 15-SEQ ID NO. 17-SEQ ID NO. 26.
In fact, as is well known to the person skilled in the art, due to the problem of codon degeneracy, in the case of defined amino acid sequences, there are numerous possibilities for their corresponding nucleic acid sequences, the preferred nucleic acid sequences mentioned above being only a preferred example and not the only possibility.
The stem cells may also comprise, express and/or secrete biologically active proteins or functional fragments thereof capable of extending the in vivo half-life of the antibody, according to techniques already disclosed in the art.
Or the stem cell comprises a nucleotide sequence encoding a biologically active protein or functional fragment thereof capable of extending the half-life of the antibody in vivo.
In some preferred embodiments, the biologically active protein or functional fragment thereof is selected from at least one of an immunoglobulin Fc domain, a serum albumin (e.g., human Serum Albumin (HSA)), an albumin binding polypeptide (e.g., HAS binding polypeptide), a prealbumin (also known as transthyretin), a carboxy terminal peptide (e.g., human chorionic gonadotrophin β subunit (CTP)), an elastin-like polypeptide (ELP), a His tag (preferably 6 xhis), a GST (glutathione-mercaptotransferase) tag, an MBP (maltose binding protein) tag, a FLAG tag, a SUMO (ubiquitin-like modifying protein) tag, and the like.
Preferably, the biologically active protein or functional fragment thereof is a human immunoglobulin Fc domain, preferably an Fc domain of human IgG, such as an Fc domain of human IgG1, igG2, igG3, igG4, more preferably an Fc domain of human IgG 1.
One or more amino acid modifications may be introduced in the Fc region or Fc domain of an antibody provided herein, thereby producing an Fc region variant. An Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, igG2, igG3, or IgG4 Fc region) comprising amino acid modifications (e.g., substitutions, deletions, and insertions) at one or more amino acid positions.
In some embodiments, any of the foregoing nucleic acid molecules are independent of, or integrated into, the genome of the modified stem cell.
In some embodiments, any of the foregoing nucleic acid molecules are operably linked to a promoter, such as a constitutive promoter, a tissue-specific promoter, or an inducible promoter.
The stem cells are selected from adult stem cells, mesenchymal stem cells, umbilical cord blood stem cells, hematopoietic stem cells, neural stem cells, adipose stem cells, skin stem cells, muscle stem cells and the like;
in the present invention, the differentiation of the stem cell type according to differentiation development potential may include:
totipotent stem cells: can differentiate into intact individuals, such as pluripotent stem cells: can differentiate into various cell tissue organs such as hematopoietic stem cells, germ stem cells, mesenchymal stem cells, neural stem cells, liver stem cells, pancreatic stem cells, etc.; monoenergetic stem cells: refers to stem cells that have the potential to differentiate into one or two related cell types, such as myoblasts in muscle, basal layer of epithelial tissue.
In the present invention, the differentiation of the types of stem cells according to the developmental stages of the stem cells may include:
Adult stem cells: under specific conditions, adult stem cells either produce new stem cells or differentiate to form new functional cells according to a program, thereby maintaining the dynamic balance of growth and deterioration of tissues and organs.
The adult stem cells include, but are not limited to:
Hematopoietic stem cells: the adult stem cells with the longest and deepest research history have the potential of differentiating into various cells of a blood system, and have great application potential in the fields of disease treatment, anti-aging health care and the like; germ stem cells: the preparation has the potential of differentiating into germ cells and various support cells of gonads, so that adults can play a fertility function and the aging of the gonads can be delayed; mesenchymal stem cells: has the potential of differentiating into organism bones, cartilages and cells of various organs, and has the characteristic immunoregulation function; neural stem cells: has the potential of differentiating into various cells of the nervous system; retinal stem cells: has the potential of differentiating into various cells of retina; cardiac stem cells: has the potential of differentiating into various cells of the heart; liver stem cells: has the potential of differentiating into various cells of the liver; pancreatic stem cells: has the potential of differentiating into various cells of pancreas, and can differentiate into islet cells under specific conditions; lung stem cells: has the potential of differentiating into various cells of the lung; renal stem cells: has the potential of differentiating into various cells of the kidney.
Preferably, the stem cells are mesenchymal stem cells.
The stem cells are isolated from cord blood, umbilical cord, placenta, adipose tissue, skin, neural tissue, or bone marrow.
According to the above, the stem cells secrete anti-interleukin antibodies.
Preferably, the stem cells secrete anti-interleukin 17 antibodies.
Further preferably, the stem cells secrete anti-IL-17A antibodies.
Based on the above stem cells, the present invention also provides:
A cell culture obtained by culturing stem cells according to the foregoing.
An extract obtained by extraction of the aforementioned cell culture.
A pharmaceutical composition comprising the aforementioned stem cells, cell cultures or extracts; optionally, the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.
In some embodiments, the adjuvant is selected from at least one of solvents, diluents, disintegrants, precipitation inhibitors, surfactants, glidants, binders, lubricants, dispersants, suspending agents, isotonic agents, thickening agents, emulsifiers, preservatives, stabilizers, hydration agents, emulsifying accelerators, buffers, absorbents, colorants, flavorants, sweeteners, ion exchangers, mold release agents, coating agents, flavoring agents, or antioxidants.
A kit comprising the aforementioned stem cell, cell culture pharmaceutical composition.
The invention also provides a preparation method of the stem cells, which comprises the following steps:
the nucleic acid molecules are introduced into stem cells by viral transfection, liposome transfection, electrotransfer, gene editing or mRNA transfection.
In some embodiments, the stem cells may be genetically modified by methods and techniques known in the art, such as physical, chemical, or biological methods, or a combination thereof, by one of skill in the art. For example, the biological methods include the use of viral vectors such as lentiviruses, retroviruses, poxviruses, herpes simplex virus I, adenoviruses, adeno-associated viruses, and the like. For example, the chemical means include colloidal dispersion systems such as macromolecular complexes, nanocapsules, microspheres, beads, and the like; lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles or liposomes, and the like. For example, the physical methods include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like.
The invention also relates to the protection of uses including, but not limited to:
The use of said stem cells, said cell culture, said extract or said pharmaceutical composition in the manufacture of a medicament for inflammatory diseases, infectious diseases, autoimmune diseases, neurological diseases and/or tumors.
The use of said stem cells, said cell culture, said extract or said pharmaceutical composition for the preparation of a diagnostic product for inflammatory diseases, infectious diseases, autoimmune diseases, neurological diseases and/or tumors.
Based on the foregoing, the present invention also provides a method for in vitro detection of IL-17A in a sample for non-diagnostic purposes.
The method comprises the following steps:
d1: the stem cells, the cell culture or the extract are contacted with a sample to be tested;
d2: detecting the antigen-antibody complex;
D3: and judging the result.
Based on the foregoing, the present invention also provides a method for preventing and/or treating a disease, the method comprising:
administering to a subject in need thereof a therapeutically effective amount of said stem cells, said cell culture, said extract or said pharmaceutical composition;
the disease is inflammatory disease, infectious disease, autoimmune disease, nervous system disease and/or tumor.
Such autoimmune diseases include, but are not limited to: behcet's disease, systemic lupus erythematosus, chronic discoid lupus erythematosus, multiple sclerosis, systemic scleroderma, progressive systemic sclerosis, scleroderma, polymyositis, dermatomyositis, perinodular arteritis, aortitis syndrome, malignant rheumatoid arthritis, juvenile idiopathic arthritis, spondyloarthritis, mixed connective tissue disease, kalman's disease, sjogren's syndrome, adult Steve's disease, vasculitis, allergic granulomatous vasculitis, allergic vasculitis, rheumatoid vasculitis, macrovasculitis, ANCA-related vasculitis, cogan syndrome, RS3PE syndrome, temporal arteritis, polymyalgia rheumatica, fibromyalgia, antiphospholipid antibody syndrome, eosinophilic fasciitis, igG 4-related diseases, guillain-Barre syndrome, myasthenia gravis, chronic atrophic gastritis, autoimmune hepatitis, inflammatory bowel disease non-alcoholic steatohepatitis, primary biliary cirrhosis, good-pasture syndrome, acute glomerulonephritis, lupus nephritis, megaloblastic anemia, autoimmune hemolytic anemia, pernicious anemia, autoimmune neutropenia, idiopathic thrombocytopenic purpura, barcedo's disease, hashimoto's disease, autoimmune adrenocortical insufficiency, primary hypothyroidism, addison's disease, idiopathic Addison's disease, type I diabetes, slowly progressive type I diabetes, focal scleroderma, psoriasis, psoriatic arthritis, bullous pemphigoid, pregnancy herpes, linear IgA bullous dermatoses, acquired bullous epidermolysis, alopecia areata, white spot, neuromyelitis, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, sarcoidosis, giant cell arteritis, amyotrophic lateral sclerosis, former disease, autoimmune optic neuropathy, idiopathic azoospermia, habitual abortion, inflammatory bowel disease, celiac disease, ankylosing spondylitis, severe asthma, chronic urticaria transplantation immunity, familial mediterranean fever, eosinophilic chronic sinusitis, dilated cardiomyopathy, systemic mastocytosis or inclusion body myositis.
Preferably, the autoimmune disease is plaque psoriasis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or lupus nephritis.
Such tumors include, but are not limited to: basal cell carcinoma, cholangiocarcinoma, bladder carcinoma, bone cancer, breast cancer, peritoneal carcinoma, cervical cancer, cholangiocarcinoma, choriocarcinoma, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, ocular cancer, head and neck cancer, gastric cancer, glioblastoma, liver cancer, renal cancer, laryngeal cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, myeloma, neuroblastoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, cancer of the respiratory system, salivary gland carcinoma, sarcoma, skin cancer, squamous cell carcinoma, testicular cancer, thyroid cancer, uterine cancer, cancer of the urinary system, B-cell lymphoma, chronic lymphoblastic leukemia, acute lymphoblastic leukemia, hairy cell leukemia or chronic myelogenous leukemia.
The invention has the beneficial effects that:
According to the invention, the recombinant antigen immune alpaca is prepared, the nano antibody with IL-17A specificity is screened, and two nano antibodies are pertinently selected for series connection, so that the obtained IL-17A specificity serial antibody has better IL-17A antigen binding capacity and blocking activity compared with a single domain antibody before series connection, can be used for modifying stem cells, particularly MSC, and has good clinical application prospect.
The modified stem cells of the present invention exhibit superior effects in a variety of animal models, including but not limited to:
(1) Collagen-induced Rheumatoid Arthritis (RA) mouse model, with respect to treatment regimen of positive antibodies Ixekizumab (1 mg/Kg) and hoc-MSC (pre-modification), at equivalent injection amounts (2×10 6/dose), both MSC treatment and G4-H10-MSC treatment groups restored mouse body weight, whereas positive antibody groups did not significantly restore mouse body weight; test endpoint G4-H10-MSC treated mice had significantly higher body weight than the positive antibody group. In terms of the average paw thickness of animals, the G4-H10-MSC treatment effect of the invention is obviously better than that of positive antibodies Ixekizumab and hUC-MSC; pathological tissue staining scores also show that the treatment effect of G4-H10-MSC is significantly better than that of positive antibodies Ixekizumab and hUC-MSC;
(2) In a psoriasis (Ps) model constructed by an imiquimod smearing method, the treatment effect of G4-H10-MSC is obviously better than that of positive antibodies Ixekizumab and hUC-MSC in animal weight, skin clinical score and skin thickness;
(3) In the model of psoriatic arthritis (PsA) constructed by injecting mannans into the abdominal cavity, the treatment effect of G4-H10-MSC is obviously better than that of positive antibodies Ixekizumab and hUC-MSC in terms of animal weight, paw joint score and skin clinical score; and also shows superior effect (with significant difference) with respect to positive antibodies Ixekizumab and hUC-MSC in terms of animal serum inflammatory factors (TNF-alpha, IL-6, IL-23).
Drawings
FIG. 1 shows the result of SDS-PAGE of IL-17A recombinant protein (antigen).
FIG. 2 shows the results of a positive control antibody Ixekizumab blocking assay.
FIG. 3 shows SDS-PAGE results of the tandem antibodies G4-H10.
FIG. 4 shows the results of the detection of the antibody affinity of the positive control antibody Ixekizumab and the tandem antibodies G4-H10 in basic experimental example 3, wherein the left panel shows the positive control antibody Ixekizumab and the right panel shows the tandem antibodies G4-H10.
FIG. 5 shows the results of the antibody blocking test of the tandem antibodies G4 to H10 in basic test example 4.
FIG. 6 shows the results of lentiviral titer assays in example 1.
Fig. 7 shows FITC channel signal detection results of the mesenchymal stem cells of example 2: the hUC-MSC reading value is 0.353%, and the G4-H10-MSC reading value is 63.329%.
FIG. 8 shows the results of measurement of the amount of IgG4 expressed in example 3.
FIG. 9 shows the results of detection of IL-17Nb antibody content in example 3.
FIG. 10 is a graph showing the results of the ability of G4-H10-MSC cells to block IL-17A/IL-17RA binding assay in example 4.
FIG. 11 shows statistics of IL17Nb expression levels of mesenchymal stem cells of example 5 at different culture times. There was a very significant difference (P < 0.001) between the hUC-MSC addition of G4-H10 and G4-H10-MSC.
FIG. 12 shows the weight statistics of each group of animals in example 6. * Representative of significant differences (P < 0.01) in the model control group compared to the normal control group; # represents a significant difference (P < 0.01) between the G4-H10-MSC treated group and the model control group; and & & represents a significant difference (P < 0.01) between the G4-H10-MSC treated group and the positive antibody treated group.
Fig. 13 is a graph showing the results of clinical scores of paw joints of animals in each group of example 6. * Representative of significant differences in model control versus normal control (P < 0.0001); # # represents significant differences between the 3 treatment groups and the model control group, respectively (P < 0.001); the & & represents that there was a significant difference between the G4-H10-MSC treated group and the positive antibody treated group (P < 0.01); the @ represents a significant difference (P < 0.05) between the G4-H10-MSC treated group and the hUC-MSC treated group.
FIG. 14 shows the results of the skin clinical scores of the animals of example 6. * Representative of significant differences in model control versus normal control (P < 0.0001); # represents a significant difference P <0.01 between the 3 treatment groups and the model control group, respectively; represents a significant difference (P < 0.05) between the G4-H10-MSC treated group and the positive antibody treated group; @represents a significant difference (P < 0.05) between the C3-H10-MSC treated group and the hoc-MSC treated group.
FIGS. 15-17 show the results of detection of inflammatory factors in serum of animals of example 6, wherein the hUC-MSC group is a hUC-MSC treated group, the positive antibody group is a positive antibody treated group, and the G4-H10-MSC group is a G4-H10-MSC treated group.
FIG. 15 shows the results of TNF- α detection in the serum of each group of animals of example 6. Wherein: * Representative of significant differences (P < 0.01) in the model control group compared to the normal control group; # represents a significant difference (P < 0.05) between the hiuc-MSC treated group and the model control group; # represents a significant difference (P < 0.01) between the G4-H10-MSC treated group and the model control group; represents a significant difference (P < 0.05) between the G4-H10-MSC treated group and the positive antibody treated group; the @ represents a significant difference (P < 0.05) between the G4-H10-MSC treated group and the hUC-MSC treated group.
FIG. 16 shows the results of IL-6 detection in serum of animals of each group of example 6. Wherein: * Representative of significant differences (P < 0.01) in the model control group compared to the normal control group; # represents a significant difference (P < 0.05) between the hiuc-MSC treated group and the model control group; # represents a significant difference (P < 0.01) between the G4-H10-MSC treated group and the model control group; represents a significant difference (P < 0.05) between the G4-H10-MSC treated group and the positive antibody treated group.
FIG. 17 shows the results of IL-23 detection in serum of animals of each group of example 6. Wherein: * Significant differences (P < 0.01) were present in the representative model control group compared to the normal control group; # represents a significant difference (P < 0.05) between positive antibody and G4-H10-MSC treated group and model control group; the @ represents a significant difference (P < 0.05) between the G4-H10-MSC treated group and the hUC-MSC treated group.
Detailed Description
The present invention will be described in further detail with reference to the following examples, which are not intended to limit the present invention, but are merely illustrative of the present invention. The experimental methods used in the following examples are not specifically described, but the experimental methods in which specific conditions are not specified in the examples are generally carried out under conventional conditions, and the materials, reagents, etc. used in the following examples are commercially available unless otherwise specified. The reagents, materials and equipment that may be involved in the present invention are shown in Table 1.
TABLE 1 Main reagents, materials and apparatus according to the invention
The primers used for screening and cloning VHH fragments and constructing nanobodies are designed by referring to the following documents:
Maass DR, Sepulveda J, Pernthaner A, Shoemaker CB. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J Immunol Methods. 2007;324(1-2):13-25.
Lin, J, Gu, Y, Xu, Y et al.Characterization and applications of nanobodies against Pseudomonas aeruginosa exotoxin a selected from single alpaca B cells. Biotechnol Biotechnol Equip 2020; 34: 1028–37.
Studies on design of single domain antibodies by AlpacaVHH phage library and high throughput sequencing toconstruct Fab antibody purification system(http: //hdl.handle.net/10232/00030916).
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly used in the art to which this invention belongs. For the purposes of explaining the present specification, the following definitions will apply, and terms used in the singular will also include the plural and vice versa, as appropriate.
The terms "a" and "an" as used herein include plural referents unless the context clearly dictates otherwise. For example, reference to "a cell" includes a plurality of such cells, equivalents thereof known to those skilled in the art, and so forth.
As used herein, the term "include" or "comprising" means "including but not limited to. The term is intended to be open ended to specify the presence of any stated features, elements, integers, steps, or components, but does not preclude the presence or addition of one or more other features, elements, integers, steps, components, or groups thereof. Thus, the term "comprising" includes the more limiting terms "consisting of … …" and "consisting essentially of … …". In one embodiment, the term "comprising" as used throughout the invention, and in particular in the claims, may be replaced by the term "consisting of … …". The amino acid three-letter codes and one-letter codes used herein are as known to those skilled in the art, or as described in J biol. Chem, 243, p3558 (1968).
As used herein, the terms "optional," "any," or "any" mean that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs or does not. For example, "optionally comprising 1 antibody heavy chain variable region" means that an antibody heavy chain variable region of a particular sequence may be, but is not required to be, present.
As used herein, the term "about" means a range of ±20% of the numerical value thereafter. In some embodiments, the term "about" means a range of ±10% of the numerical value following that. In some embodiments, the term "about" means a range of ±5% of the numerical value following that.
As used herein, the term "stem cell" refers to an undifferentiated cell that self-renews and differentiates at the single cell level to produce daughter cells, including self-renewing progenitor cells, non-renewing progenitor cells, and terminally differentiated cells. The stem cells have unlimited self-renewal, proliferation and differentiation capacity under certain conditions, can generate daughter cells with the same phenotype, genotype and self, can also generate specialized cells composing tissues and organs of the organism, and plays a main role in body growth, maintenance, renewal and injury repair.
As used herein, the term "mesenchymal stem cells", also known in the art as "mesenchymal stem cells (MESENCHYMAL STEM CELL, MSC)", refers to a group of multipotent stromal cell populations derived from mesoderm that have a certain differentiation potential and can differentiate into a variety of cell types. It is derived mainly from and is present in bone marrow, and in addition includes multipotent cells that are widely derived from other "non-bone marrow" tissues, such as: placenta, umbilical cord blood, adipose tissue, adult muscle, cornea stroma, tooth pulp of deciduous teeth, etc.
As used herein, the term "IL-17A", "interleukin-17A" or "IL-17" refers to a cytokine, belonging to the interleukin 17 family, produced by T cells and other types of immune cells, and playing an important role in the immune system. IL-17A is produced primarily by Th17 cells, and other cells including CD8+ T cells, γδ T cells, NK cells and neutrophils, mast cells and macrophages also express IL-17A. It acts primarily on immune cells, such as macrophages, neutrophils and endothelial cells, inducing an inflammatory response. In some examples, the term includes variants, homologs, orthologs, and paralogs. For example, antibodies specific for human IL-17A may in some cases cross-react with IL-17A protein of another species, such as a monkey. In other embodiments, antibodies specific for human IL-17A protein may be completely specific for human IL-17A protein without cross-reacting with other species or other types of proteins, or may cross-react with IL-17A proteins of some other species but not all other species.
As used herein, the terms "anti-IL-17A single domain (nanobody," IL-17A single domain (nanobody) "or" tandem single domain (nanobody) that specifically binds IL-17A refer to an antibody that specifically binds IL-17A and partially or fully neutralizes, inhibits or attenuates IL-17A activity, and/or inactivates IL-17A, prevents IL-17A responses, or downstream pathways mediated by IL-17A or other IL-17A mediated functions.
As used herein, the term "antibody" refers to a glycoprotein comprising a heavy chain (H) and a light chain (L) interconnected by disulfide bonds (S-S). Each heavy chain consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region (abbreviated herein as CH). The heavy chain constant region consists of 3 domains, CH1, CH2 and CH 3. Each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region (abbreviated herein as VH). The light chain constant region consists of one domain CL. Light chains fall into two categories, kappa-type light chains and lambda-type light chains, respectively (e.g., light chain constant regions Ckappa/lambda in the present invention mean that the light chain constant regions are kappa-type light chains or lambda-type light chains). The VH and VL regions may be further subdivided into hypervariable regions (also known as Complementarity Determining Regions (CDRs)) with more conserved framework or Framework Regions (FR) interposed therebetween. Each VH and VL consists of three CDRs and 4 FRs, arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Antibodies include monospecific antibodies, bispecific antibodies, and multispecific antibodies so long as they exhibit the desired biological activity or function.
As used herein, the term "single domain antibody" (sdAb) or "nanobody" has its ordinary meaning in the art and refers to an antibody fragment having a molecular weight of only 12-15 kDa, which consists of a single monomeric variable antibody domain derived from a heavy chain. Such single domain antibodies (designated VHH) can be found in camelidae mammals and naturally lack the light chain. For a general description of (single) domain antibodies, reference is also made to the above-mentioned prior art and EP 0368684, ward et al (Nature 1989 Oct 12;341 (6242): 544-6), holt et al Trends Biotechnol, 2003, 21 (11): 484-490; and WO 06/030220, WO 06/003388. The amino acid sequence and structure of a single domain antibody can be considered to consist of four framework regions or "FR", which are referred to in the art as "framework region 1" or "FR1", respectively; "frame region 2" or "FR2"; is "frame region 3" or "FR3"; "frame region 4" or "FR4"; the framework regions are separated by three complementarity determining regions or "CDRs", referred to in the art as "complementarity determining region 1" or "CDR1", respectively; "complementarity determining region 2" or "CDR2", and "complementarity determining region 3" or "CDR3". Thus, a single domain antibody can be defined as an amino acid sequence having the general structure: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, wherein FR1-FR4 refers to framework regions 1-4, respectively, and wherein CDR1-CDR3 refers to complementarity determining regions 1-3. In the context of the present disclosure, the amino acid residues of a single domain antibody are numbered according to the common numbering of the VH domains given by the International ImMunoGeneTics information system amino acid numbering (http:// imgt. Cmes. Fr /).
As used herein, the term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as modified amino acids such as hydroxyproline, gamma-carboxyglutamic acid, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., a carbon bound to hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. These analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to compounds that differ in structure from the general chemical structure of an amino acid, but function in a manner similar to naturally occurring amino acids.
As used herein, the terms "activity," "functional activity," or "biological activity," or the terms "biological property" or "biological feature" are used interchangeably herein to include, but are not limited to, epitope/antigen affinity and specificity, the ability to neutralize or antagonize IL-17A activity in vivo or in vitro, IC50, in vivo stability of an antibody, and immunogenic properties of an antibody. Other identifiable biological properties or characteristics of antibodies known in the art include, for example, cross-reactivity (i.e., cross-reactivity with non-human homologs of the targeting peptide in general, or with other proteins or tissues), and the ability to maintain high levels of expression of the protein in mammalian cells. The aforementioned properties or characteristics are observed, assayed or assessed using techniques well known in the art, including but not limited to ELISA, FACS or BIACORE plasma resonance analysis, unrestricted in vitro or in vivo neutralization assays, receptor binding, cytokine or growth factor production and/or secretion, signal transduction, and immunohistochemistry of tissue sections of different origin (including human, primate or any other source).
As used herein, the term "Fc" or "Fc region" or "Fc fragment" refers to a polypeptide consisting of the CH2 and CH3 domains of IgA, igD, and IgG, or the CH2, CH3, and CH4 domains of IgE and IgM through a hinge region. Although the breakdown of the Fc fragment is variable, the heavy chain Fc fragment of human IgG generally refers to the polypeptide from A231 to its carboxy terminus.
As used herein, the term "epitope" refers to a protein determinant capable of specific binding to an antibody. Epitopes are typically composed of surface-clustered molecules, such as amino acids or sugar side chains, and typically have specific three-dimensional structural features, as well as specific charge features. Conformational and non-conformational epitopes differ in that binding to the former but not the latter is lost in the presence of denaturing solvents. Epitopes can include amino acid residues that are directly involved in binding and other amino acid residues that are not directly involved in binding, such as amino acid residues that are effectively blocked or covered by a specific antigen binding peptide (in other words, amino acid residues are within the footprint of a specific antigen binding peptide).
As used herein, the term "affinity" or "binding affinity" refers to an inherent binding affinity that reflects interactions between members of a binding pair. The affinity of a molecule X for its partner Y can be generally represented by the equilibrium dissociation constant (KD), which is the ratio of the dissociation rate constant and the binding rate constant (K off and K on, respectively). Affinity can be measured by common methods known in the art. One specific method for measuring affinity is the ForteBio kinetic binding assay herein.
As used herein, the term "high affinity" or "high affinity" for IgG antibodies refers to KD for an antigen of 1.0 x 10 -6 M or less, preferably 5.0 x 10 -8 M or less, more preferably 1.0 x 10 -8 M or less, 5.0 x 10 -9 M or less, more preferably 1.0 x 10 -9 M or less. For other antibody subtypes, "high affinity" binding may vary. For example, "high affinity" binding of IgM subtype refers to KD of 10 -6 M or less, preferably 10 -7 M or less, more preferably 10 -8 M or less.
As used herein, the term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in single or double stranded form. Unless specifically limited, the term includes nucleic acids containing known analogues of natural nucleotides that have similar binding properties to the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides (see, U.S. Pat. No. 8278036 to Kariko et al, which discloses mRNA molecules with uridine replaced by pseudouridine, methods of synthesizing the mRNA molecules, and methods for delivering therapeutic proteins in vivo). Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is replaced with a mixed base and/or deoxyinosine residue (Batzer,Nucleic Acid Res. 19: 5081 (1991); Ohtsuka,J.Biol.Chem. 260: 2605-2608 (1985); Rossolini,Mol.Cell.Probes8: 91-98 (1994)).
As used herein, the term "construct" refers to any recombinant polynucleotide molecule (such as a plasmid, cosmid, virus, autonomously replicating polynucleotide molecule, phage, or linear or circular single-stranded or double-stranded DNA or RNA polynucleotide molecule), derived from any source, capable of integrating with the genome or autonomously replicating, constituting a polynucleotide molecule in which one or more polynucleotide molecules have been functionally linked (i.e., operably linked). Recombinant constructs will typically comprise a polynucleotide of the invention operably linked to transcriptional initiation regulatory sequences that direct the transcription of the polynucleotide in a host cell. Both heterologous and non-heterologous (i.e., endogenous) promoters may be used to direct expression of the nucleic acids of the invention.
As used herein, the term "vector" refers to any recombinant polynucleotide construct that can be used for transformation purposes (i.e., introducing heterologous DNA into a host cell). One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, in which additional DNA segments can be ligated into the viral genome. Some vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Upon introduction into a host cell, other vectors (e.g., non-episomal mammalian vectors) integrate into the genome of the host cell and thereby replicate together with the host genome. In addition, certain vectors are capable of directing the expression of genes that are operably linked. Such vectors are referred to herein as "expression vectors".
As used herein, the term "expression vector" refers to a nucleic acid molecule capable of replicating and expressing a gene of interest when transformed, transfected or transduced into a host cell. The expression vector contains one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to provide amplification in the host if desired.
As used herein, the term "pharmaceutical composition" generally refers to a formulation that exists in a form that allows for the biological activity of the active ingredient to be effective and that does not contain additional ingredients that have unacceptable toxicity to the subject to which the composition is to be administered. The composition is sterile.
As used herein, the term "pharmaceutically acceptable" refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. As used herein, the term "pharmaceutically acceptable carrier, excipient, and/or diluent" refers to a carrier that is pharmacologically and/or physiologically compatible with the subject and active ingredient, is well known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995). pharmaceutically acceptable materials, compositions, or vehicles, such as liquid or solid fillers, diluents, excipients, solvents, media, encapsulating materials, manufacturing aids, or solvent encapsulating materials, which are involved in maintaining the stability, solubility, or activity of the antibodies or antigen binding fragments thereof of the present disclosure, and include, but are not limited to, pH-adjusting agents, surfactants, adjuvants, ionic strength enhancers, diluents, agents that maintain osmotic pressure, agents that delay absorption, preservatives, e.g., pH-adjusting agents including, but not limited to phosphate buffers, surfactants including, but not limited to, cations, anions, or nonionic surfactants, e.g., tween-80, ionic strength enhancers including, but not limited to sodium chloride, preservatives including, but not limited to, various antibacterial and antifungal agents, e.g., parabens, triclosan, phenol, osmotic acids, including, but not limited to, aqueous buffers, e.g., sorbitol, such as well as saline, and glycerol, such as saline, and other stabilizing agents, such as saline, and glycerol, such as saline, and saline, such as saline, and other stable, such agents are understood by the art, which is capable of stabilizing the desired activity of the active ingredient in a medicament, including, but not limited to, sodium glutamate, gelatin, SPGA, saccharides (e.g., sorbitol, mannitol, starch, sucrose, lactose, dextran, or glucose), amino acids (e.g., glutamic acid, glycine), proteins (e.g., dried whey, albumin or casein) or degradation products thereof (e.g., lactalbumin hydrolysate), and the like.
Basic Experimental example 1IL-17A nanobody screening
As shown in the invention patent on the same date as the application, the invention screens antibodies by immunizing animals with antigen, and comprises the following steps:
(1) Preparation of recombinant antigens
Adding a6 XHis tag at the C end of the IL-17A antigen, performing gene synthesis after prokaryotic codon optimization, and subcloning the gene into a pET28a vector; after being verified by Sanger sequencing, the plasmid is extracted; transforming the recombinant plasmid into BL21 competent, inducing overnight with 0.5mM IPTG, and collecting bacterial liquid for cleavage; the recombinant protein was purified to a purity of greater than 90% using a nickel column. (FIG. 1)
(2) Positive control antibody: preparation of Enoki monoclonal antibody (Ixekizumab)
Ixekizumab heavy chain variable region: SEQ ID NO. 20; the light chain variable region SEQ ID NO. 21.
SDS-PAGE detects the purity of the positive control antibody protein >95%.
SEQ ID NO:20:
QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG;
SEQ ID NO:21:
DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.
(3) Construction and verification of IL-17A reporter gene cell strain
Based on the amino acid sequence information of IL-17RA (UniProtKB: Q96F 46) and IL-17RC (UniProtKB: Q8NAC 3), a lentiviral expression vector is constructed, lentivirus is packaged, 293 cells are co-infected, recombinant 293 cells which simultaneously overexpress the two receptors are screened, NFKB-Luciferase and ACT1 genes are further stably transformed, and an IL-17A reporter cell strain 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc is constructed. And adding a recombinant antigen for activation, and simultaneously adding a positive control antibody Ixekizumab for detection of a blocking experiment, so as to establish a candidate antibody in vitro pharmacodynamics evaluation cell strain targeting IL-17A. The constructed IL-17A receptor over-expression cell strain can be combined with IL-17A, and the IL17A recombinant protein can effectively activate luciferase expression in 293F-IL17Ra/IL17 Rc-NFkB-Luc reporter gene cell strain.
The positive control antibody Ixekizumab and the IL-17A recombinant protein are added into 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc cells together, and the positive control antibody Ixekizumab can inhibit the combination of IL17A protein and a membrane receptor thereof and inhibit the signal of intracellular NFkB and present a dose effect. The results are shown in FIG. 2.
(4) Alpaca immunity
The recombinant antigen protein prepared above is used for immunizing alpaca (Alpaca), the immunization interval is 21 days, after the last immunization is 10 days, part of peripheral blood is collected, and ELISA detection of immune effect is adopted for separating serum.
(5) Detection of immune titers
The immunological titers of alpaca reached the requirements after 6 rounds of immunization (see tables 2-3 below).
TABLE 2 results of immunotiter assays
TABLE 3 results of immunotiter assays
(6) PBMC isolation and VHH antibody fragment cloning
PBMC were isolated, RNA was extracted and subjected to two rounds of PCR after reverse transcription, the products were recovered, and the concentration was determined.
(7) Construction and panning of Single-Domain antibody Yeast display libraries
The linear vector and the PCR product together electrically transformed the yeast competent strain. Single domain antibody yeast display library panning; after panning, yeast monoclonal was subjected to flow detection. Amplification of overlapping PCR (Overlap PCR) products, transient transfection and detection, recovery of the products, transfection. ELISA was used to select positive clones, VHH antibody sequences were obtained and gene synthesis was performed, and Protein A (Protein A) was purified after genetic engineering expression.
Enriching positive clones; selecting the enriched monoclonal, carrying out PHAGE ELISA identification, and carrying out sequencing analysis on the clone to obtain the nucleic acid and amino acid sequence information of the candidate single domain antibody. 20 monoclonals are randomly selected for sequencing analysis, the sequence difference is large, and the library diversity is good. The potential post-translational modification sites were analyzed by the In silico method against the amino acid sequence information of the CDR regions of the candidate single domain antibodies.
According to the result of the monoclonal flow detection of the yeast, positive clones combined with IL-17A-His are selected to extract genome DNA, and the antibody sequence is obtained by PCR. Selecting differential clones for overlapping PCR amplification, adding a signal peptide to the N end of VHH, adding IgG1-Fc to the C end, and transiently transfecting HEK293 cells with PCR products; ELISA detection was performed on the expressed antibody supernatants: 100 mu L of transfection supernatant is added into a 96-well plate pre-coated by IL-17A recombinant antibody for incubation, ELISA detection is carried out by adopting HRP-Protein A as a secondary antibody, and differential cloning is arranged for constructing eukaryotic expression vectors. The constructed single domain antibody expression vector is transiently transfected into 293F cells, and recombinant antibodies are affinity purified by using Protein A.
(8) ELISA detects the combination of the recombinant antibody and the target protein, FACS detects the combination of the single domain antibody and the reporter gene cell strain to complete the single domain antibody blocking function experiment, and the ForteBio OCTET R2 system carries out dynamic characterization analysis. Kinetic characterization analysis was performed using the ForteBio OCTET R2 system. Screening was performed based on the results of all antibodies. The invention further extends to the basis of the basic screening method described above. In the detection of the blocking activity of the antibody, the blocking effect of a part of single domain antibodies is weaker than that of a positive antibody Ixekizumab although the single domain antibodies can block the Human IL-17A protein from activating a downstream target protein. Therefore, two anti-IL-17A single domain antibodies are serially connected to form a bivalent antibody so as to enhance the blocking effect, and relevant stem cells are prepared on the basis and the application of the stem cells in preparing medicines is verified. Specifically, the invention protects stem cells prepared by serial antibodies constructed by serial numbers of 2-G4 (G4 for short) and 3-H10 (H10 for short), and the subsequent serial antibodies are called G4-H10 for short.
Basic Experimental example 2 preparation and purification of IL-17A-specific tandem antibodies
2-G4 has the sequence of SEQ ID NO 16, and CDR regions have the sequence of SEQ ID NO 1-3;
3-H10 has the sequence of SEQ ID NO. 17, and the CDR regions have the sequence of SEQ ID NO. 4-6.
Also included in the tandem antibody are a linker (GGGGS) 3, a hinge region and a CH region.
The sequence of the constructed tandem antibody is SEQ ID NO. 18. The coding gene of the tandem antibody is SEQ ID NO. 19.
SEQ ID NO: 18:
QVQLVESGGGLVQPGGSLRLSCAASGEKLDYFAIGWFRQAPGKEREVVSCVTSSGSSTNYLSSVKDRFTISIDNAKNTVYLQMNSLKPEDTAIYYCASTILLCSDYISAFGTWGQGTQVTVASGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSIHIYAMGWYRQAPGKQRELVATITRGGVTNNADSVKGRFTISRDNAKNTAYLQMNSLKPEDTAVYYCNAGGTNGGYWGQGTQVTVSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.
SEQ ID NO:19:
CAGGTGCAGCTCGTGGAGTCGGGGGGAGGCTTGGTGCAGCCCGGGGGATCTCTGAGGCTCTCGTGTGCAGCCTCTGGAGAGAAATTGGATTATTTTGCCATAGGCTGGTTCCGCCAGGCCCCAGGGAAGGAGCGTGAGGTAGTCTCATGTGTCACAAGTAGTGGTAGTAGCACAAACTATTTAAGTTCCGTGAAGGACCGATTCACCATCTCCATAGACAACGCCAAGAACACGGTATATCTGCAAATGAACAGCCTGAAACCTGAGGACACAGCCATTTATTACTGTGCGTCCACTATTCTCCTCTGTTCAGATTATATCTCTGCCTTTGGCACCTGGGGCCAGGGGACCCAGGTCACCGTCGCCTCGGGAGGCGGAGGATCTGGCGGAGGTGGAAGTGGCGGAGGCGGTTCTGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTGCAGCCGGGGGGGTCTCTGAGACTCTCCTGTGCAGCCTCTGGATTTAGTATCCACATCTATGCCATGGGCTGGTACCGCCAGGCTCCAGGGAAGCAGCGCGAGCTGGTCGCAACTATTACTAGAGGTGGTGTAACAAATAATGCAGACTCCGTGAAGGGGCGATTCACCATCTCCAGAGACAACGCCAAGAACACGGCGTATCTGCAAATGAACAGCCTGAAACCTGAGGACACGGCCGTCTATTACTGTAATGCAGGTGGGACGAACGGGGGCTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCA.
The tandem antibodies can be prepared by reference to the prior art antibody preparation methods, specifically as follows:
(1) The SEQ ID NO. 19 gene is synthesized and subcloned into an expression vector pcDNA3.4-hIgG1-Fc in series with the human IgG1 Fc segment gene sequence. After the vector was verified by sequencing, the endotoxin-free plasmid was prepared using the Qiagen plasmid large-sample kit (CAT#: DP 117) for use.
(2) Taking out LVTransm transfection reagent and single-chain antibody expression vector from refrigerator, thawing at room temperature, and blowing with pipetting gun. The PBS buffer was removed and warmed to room temperature. Taking 2mL of PBS to one hole of a 6-hole plate, respectively adding 130 mug antibody expression vector, blowing up and down by a pipette to fully mix, adding 400 mug L LVTRANSM, immediately blowing up and down by the pipette to mix, and standing for 10 minutes at room temperature to obtain the DNA/LVTransm compound.
(3) The DNA/LVTransm complex was added to 30mL of 293F cells and mixed thoroughly with gentle shaking. After the cells were placed in a 37℃5% CO 2 incubator at 130rpm for 6-8 hours, 50mL of fresh 293 cell medium was added and the cells were returned to the incubator for continued culture.
After 7 days of continuous culture, the culture supernatant was collected by centrifugation, filtered with a 0.45 μm filter membrane, and the filtrate was transferred to a sterile centrifuge tube, and the antibody was purified using Protein A to obtain a purified single domain antibody.
SDS-PAGE results of the tandem antibodies G4-H10 are shown in FIG. 3.
SDS-PAGE detects the purity of the target antibody protein, and the result shows that the protein purity is >95%.
Basic Experimental example 3IL-17A specific tandem antibody affinity assay
Using Ixekizumab as a positive control antibody, synthesizing Ixekizumab heavy chain and light chain variable regions by genes, subcloning the heavy chain variable regions into pcDNA3.4-hIgG4 (hIgG 4 amino acid sequence is SEQ ID NO: 22) vectors, and subcloning the light chain variable regions into pcDNA3.4-hIgKc (hIgKc amino acid sequence is SEQ ID NO: 23) vectors; after verification by Sanger sequencing, the plasmid megapump kit is used for preparing the endotoxin-removing plasmid for standby. Other steps reference basic Experimental example 2, control antibodies were prepared with purity >95%.
SEQ ID NO:22:
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK;
SEQ ID NO:23:
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.
ELISA detects binding of recombinant antibodies to target proteins:
Coating an ELISA plate with the purified antibody to be detected (2 ug/mL), adding Biotin-IL-17A-His, diluting 7 points with a 5-fold gradient, performing ELISA detection with HRP-STREPTAVDIN, and drawing a curve of OD450 values measured by each concentration to read EC50 values.
The results showed that the positive control antibody Ixekizumab had an EC50 value of 10.06 μg/mL; the EC50 of the tandem antibody was 1.177. Mu.g/mL. See fig. 4.
Basic Experimental example 4 antibody blocking function experiment
Blocking activity assays were performed using the 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc reporter cell line. The tandem antibody of basic experimental example 2 and the positive control antibody Ixekizumab of basic experimental example 3 were detected.
Based on the amino acid sequence information of IL-17RA (UniProtKB: Q96F 46) and IL-17RC (UniProtKB: Q8NAC 3), a lentiviral expression vector is constructed, lentivirus is packaged, 293 cells are co-infected, recombinant 293 cells which simultaneously overexpress the two receptors are screened, NFKB-Luciferase (SEQ ID NO: 24) and ACT1 gene (SEQ ID NO: 25) are further stably transformed, and an IL-17A reporter cell strain 293F-IL-17RA-IL-17Rc-ACT1-nfκB-Luc is constructed.
SEQ ID NO:24:
atggaagatgccaaaaacattaagaagggcccagcgccattctacccactcgaagacgggaccgccggcgagcagctgcacaaagccatgaagcgctacgccctggtgcccggcaccatcgcctttaccgacgcacatatcgaggtggacattacctacgccgagtacttcgagatgagcgttcggctggcagaagctatgaagcgctatgggctgaatacaaaccatcggatcgtggtgtgcagcgagaatagcttgcagttcttcatgcccgtgttgggtgccctgttcatcggtgtggctgtggccccagctaacgacatctacaacgagcgcgagctgctgaacagcatgggcatcagccagcccaccgtcgtattcgtgagcaagaaagggctgcaaaagatcctcaacgtgcaaaagaagctaccgatcatacaaaagatcatcatcatggatagcaagaccgactaccagggcttccaaagcatgtacaccttcgtgacttcccatttgccacccggcttcaacgagtacgacttcgtgcccgagagcttcgaccgggacaaaaccatcgccctgatcatgaacagtagtggcagtaccggattgcccaagggcgtagccctaccgcaccgcaccgcttgtgtccgattcagtcatgcccgcgaccccatcttcggcaaccagatcatccccgacaccgctatcctcagcgtggtgccatttcaccacggcttcggcatgttcaccacgctgggctacttgatctgcggctttcgggtcgtgctcatgtaccgcttcgaggaggagctattcttgcgcagcttgcaagactataagattcaatctgccctgctggtgcccacactatttagcttcttcgctaagagcactctcatcgacaagtacgacctaagcaacttgcacgagatcgccagcggcggggcgccgctcagcaaggaggtaggtgaggccgtggccaaacgcttccacctaccaggcatccgccagggctacggcctgacagaaacaaccagcgccattctgatcacccccgaaggggacgacaagcctggcgcagtaggcaaggtggtgcccttcttcgaggctaaggtggtggacttggacaccggtaagacactgggtgtgaaccagcgcggcgagctgtgcgtccgtggccccatgatcatgagcggctacgttaacaaccccgaggctacaaacgctctcatcgacaaggacggctggctgcacagcggcgacatcgcctactgggacgaggacgagcacttcttcatcgtggaccggctgaagagcctgatcaaatacaagggctaccaggtagccccagccgaactggagagcatcctgctgcaacaccccaacatcttcgacgccggggtcgccggcctgcccgacgacgatgccggcgagctgcccgccgcagtcgtcgtgctggaacacggtaaaaccatgaccgagaaggagatcgtggactatgtggccagccaggttacaaccgccaagaagctgcgcggtggtgttgtgttcgtggacgaggtgcctaaaggactgaccggcaagttggacgcccgcaagatccgcgagattctcattaaggccaagaagggcggcaagatcgccgtg;
SEQ ID NO:25:
ATGCCACCTCAGTTGCAGGAAACTCGGATGAATAGAAGCATCCCCGTGGAAGTGGACGAGAGCGAGCCGTACCCTAGTCAGCTGCTGAAGCCGATCCCTGAGTACTCCCCGGAAGAGGAATCCGAACCACCAGCCCCCAACATTCGCAATATGGCCCCCAATAGCTTGTCCGCACCAACAATGCTGCACAACTCTTCTGGCGACTTCTCTCAGGCCCACTCCACCCTGAAACTGGCGAATCACCAGCGGCCTGTATCCCGGCAGGTGACCTGTCTGAGAACTCAGGTGCTTGAAGACTCCGAGGACTCTTTCTGTAGGCGGCATCCAGGTTTGGGCAAGGCGTTTCCGTCCGGCTGTTCCGCGGTTTCAGAGCCCGCTTCCGAAAGTGTCGTGGGCGCCCTGCCAGCCGAGCACCAGTTCTCCTTCATGGAAAAGCGGAACCAGTGGCTGGTCAGTCAGCTGAGCGCCGCGTCACCTGATACAGGTCACGATTCCGACAAGTCTGACCAGTCTCTGCCCAATGCGTCAGCCGATAGTCTCGGGGGCTCCCAGGAGATGGTGCAGAGACCACAGCCGCACAGAAACCGGGCCGGGCTTGATCTGCCCACCATTGATACAGGCTACGATTCCCAGCCCCAGGACGTCCTTGGCATTCGCCAGCTGGAAAGGCCTCTGCCCTTGACCTCCGTGTGTTACCCCCAGGACCTGCCCCGCCCTTTGAGAAGCCGGGAGTTTCCCCAGTTTGAGCCCCAACGATACCCTGCCTGTGCTCAGATGCTGCCTCCGAACCTGAGCCCACACGCTCCCTGGAACTACCACTATCACTGTCCCGGCAGCCCCGATCACCAGGTGCCTTATGGACACGACTACCCGCGGGCTGCATACCAGCAGGTCATACAGCCTGCCTTGCCGGGTCAGCCGCTGCCCGGAGCTTCTGTGCGCGGCCTGCACCCCGTTCAGAAAGTGATCCTGAACTATCCAAGCCCATGGGACCATGAAGAGAGACCAGCCCAAAGAGATTGCTCTTTTCCTGGGTTGCCTAGACACCAAGACCAGCCTCACCACCAGCCTCCCAATCGGGCAGGCGCCCCAGGCGAAAGTCTCGAGTGCCCCGCCGAACTCAGACCACAGGTCCCTCAGCCCCCTTCCCCCGCGGCAGTACCCAGACCCCCCTCTAACCCACCCGCCCGGGGAACGCTCAAGACTTCAAATCTCCCAGAAGAGCTGCGCAAAGTGTTCATAACCTACAGCATGGACACCGCTATGGAGGTGGTTAAGTTCGTCAACTTCCTGCTGGTCAATGGGTTCCAGACTGCAATCGACATTTTTGAGGATAGAATTCGGGGAATCGACATCATCAAGTGGATGGAGAGATACCTGCGGGATAAGACAGTGATGATTATCGTGGCCATTAGTCCCAAGTACAAGCAAGATGTGGAGGGCGCAGAATCACAGTTGGACGAAGACGAGCACGGACTCCATACAAAATATATCCACAGGATGATGCAGATCGAGTTCATTAAACAAGGCTCCATGAATTTCCGCTTCATACCGGTCCTGTTTCCAAACGCAAAAAAAGAGCATGTACCCACTTGGCTCCAGAATACCCATGTCTACTCCTGGCCCAAGAACAAGAAGAATATCCTGCTGCGCTTGCTCAGAGAAGAAGAGTATGTCGCCCCTCCAAGGGGGCCCCTCCCCACACTCCAAGTAGTGCCACTT.
The results show that Ixekizumab and the tandem antibody can block Human IL-17A protein from activating 293F-IL-17RA-IL-17Rc-ACT 1-NFkB-Luc, the IC50 values are 2.235nM and 0.5888nM respectively, and the tandem antibody is superior to the control antibody. Ixekizumab blocking assay results are shown in FIG. 2 and tandem antibody blocking assay results are shown in FIG. 5.
Basic experimental example 5 stability experimental procedure and result analysis:
The experimental process comprises the following steps: the fluorescence change is detected by a micro-differential scanning fluorescence technology (nanoDSF), so that the thermal denaturation and chemical denaturation of the protein can be detected under natural conditions, and the temperature (Tm) when 50% of the protein is in an unfolded state and the temperature (Tagg) when aggregation begins to occur can be accurately determined; the higher the thermal denaturation Tm value and Tagg, the more stable the antibody protein.
Taking 100 mu L of antibody to be detected, centrifuging at 4 ℃ for 10min at 12000 Xg, sucking samples by using capillaries, preparing two capillaries for each sample, taking the capillaries as parallel control, sequentially placing the capillaries into corresponding clamping grooves, ensuring that the capillaries are full of the samples, and carrying out detection analysis. The temperature rising range is 20-95 ℃, the temperature rising rate is 1 ℃/min, and the detection time is 75min.
Tm is defined as the melting temperature, tonset is defined as the temperature at which unfolding begins, tagg is defined as the aggregation temperature.
The antibody to be detected was the tandem antibody according to basic experimental example 2, and the positive control antibody Ixekizumab according to basic experimental example 3.
Ixekizumab results: t m1 is 56.10+/-0.02 ℃; t m2 is 79.84+/-0.13 ℃; t onset is 47.50 +/-0.08 ℃; t agg is 61.86+/-0.23 ℃; results of tandem antibodies: the value of T m1 is 58.13 +/-0.06 ℃; t m2 is 82.43 +/-0.48 ℃; t onset is 51.28 +/-0.22 ℃; t agg was found to be 58.48.+ -. 0.00 ℃.
EXAMPLE 1LV-G4-H10 Fc lentivirus preparation and detection methods
1. Lentiviral shuttle plasmid construction
Construction of a lentiviral shuttle plasmid of the G4-H10 Fc fusion protein, the VHH sequences (SEQ ID NO: 16-17) of two candidate antibodies (IL-17 Nb) of 2-G4 and 3-H10 were linked by (GGGGS) 3 and then were constructed on the lentiviral shuttle plasmid in a form of tandem connection with IgG4 Fc (the amino acid sequence of IgG4 Fc is shown as SEQ ID NO: 26, and the nucleotide sequence is shown as SEQ ID NO: 27) to form a VHH- (GGGGS) 3 -VHH-IgG4 Fc sequence downstream of the EF-1alpha promoter, thereby obtaining the G4-H10 Fc lentiviral shuttle plasmid.
SEQ ID NO: 27:
GCCCCCGAGTTTCTGGGAGGACCTAGCGTCTTTCTGTTCCCCCCCAAACCCAAGGACACACTGATGATCTCTAGGACCCCCGAGGTGACATGCGTCGTGGTGGACGTGAGCCAAGAGGACCCCGAGGTGCAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCACAATGCCAAGACCAAACCTAGAGAAGAGCAGTTCAACAGCACCTATAGAGTGGTGAGCGTGCTGACCGTGCTGCACCAAGACTGGCTGAACGGCAAGGAGTACAAGTGCAAAGTGAGCAACAAGGGCCTCCCCTCCTCCATCGAGAAAACCATCTCCAAGGCCAAGGGACAGCCTAGAGAGCCCCAAGTGTATACACTGCCCCCCAGCCAAGAGGAGATGACCAAGAACCAAGTGTCTCTGACATGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCTGTGGAGTGGGAGAGCAACGGCCAGCCCGAAAACAACTATAAGACCACCCCCCCCGTGCTGGACTCCGATGGCAGCTTCTTTCTGTACTCCAGACTGACCGTGGACAAAAGCAGATGGCAAGAGGGCAACGTGTTTAGCTGCTCCGTGATGCATGAGGCTCTGCACAACCACTATACCCAGAAGTCCCTCTCTCTGAGCCTCGGCAAGTGA.
2. Lentivirus preparation (Virus Package)
Lentivirus packaging was preceded by 24h, shake flasks were prepared and HEK293T (available from ATCC under the trade designation CRL-3216) cell density was adjusted to 1.0X10 6/mL, 60 per flask mL for use.
Preparation of transfection reagent/DNA complexes: 7.5 mL of 293T culture medium is taken to a 15 mL centrifuge tube, 40 [ mu ] g G-H10 of Fc lentiviral shuttle plasmid, 80 [ mu ] g of auxiliary plasmid (purchased from addGene, with the product numbers of 12253 and 12259), a pipette is used for blowing up and down and fully and uniformly mixing, 360 [ mu ] L of transfection reagent is added, a 1 mL pipette is used for blowing up and down and uniformly mixing immediately, and 10 min (not more than 15 min) is stood at room temperature.
The transfection reagent/DNA complex is added dropwise to the cells prepared the day before, shake the shake flask while adding, and after thoroughly mixing, the shake flask is placed on a shaking table of 5% CO 2, 120 rpm at 37 ℃ for culture.
After 24h incubation, the supernatant was collected and filtered into a virus centrifuge tube using a 0.45 μm needle filter, 45000 Xg, 4℃and centrifuged at 90 min.
After centrifugation, the supernatant was decanted and the residual supernatant was removed using a pipette, the pellet was resuspended in 1 mL PBS and split-packed into virus split-tubes, 100 μl each, i.e. LV-G4-H10: fc lentivirus.
3. Lentivirus titer detection
The 293T cells are inoculated into 24-well plates, after overnight culture, 20 mu L LV-G4-H10 of Fc virus stock solution, 10 times of diluted virus solution and 100 times of diluted virus solution are respectively added, the culture is continued for 24 hours, fresh culture medium is replaced after 24 hours, after continuous culture for 9 days, the cells are harvested, genomic DNA (the kit is purchased from Thermo, the product number is K0721), ddH 2 O (double distilled water) is used for adjusting the copy number of a plasmid template, the standard curve range is 1X 10 9-1×103, primers are synthesized by Souzhou Jin Weizhi biotechnology Co, 2X PCR Mix (purchased from Applied Biosystems, ABI, applied biosystems Co., USA, product number is A25742), primers, DNA and PCR water (purchased from Thermo, simer, product number is R0582) are evenly mixed and then added into corresponding PCR reaction wells for PCR reaction. And the titer of the virus was calculated according to the following formula:
lentiviral titer = cell number x copy number/viral volume (mL) x dilution.
The results of lentiviral titer assays are shown in FIG. 6, and no matter whether the virus was primary or diluted 10-fold or 100-fold, the virus titer was between 2.3E+7 and 2.6E+7, with no significant differences between the three groups, so the lentiviral titer was 2.45E+7 TU/mL.
Example 2 preparation of G4-H10 Gene-modified Stem cells (G4-H10-MSC) and detection of infection efficiency
The prepared LV-G4-H10 is added with mesenchymal stem cells which are cultured and have the fusion degree of 70-80 percent (the mesenchymal stem cells are separated from neonatal umbilical cords by using an enzymolysis method and are obtained by means of generation amplification and purification), the mesenchymal stem cells are cultured at 37 ℃ and CO 2, and after the cell density reaches 100 percent, the mesenchymal stem cells infected with LV-G4-H10 are passaged, and the mesenchymal stem cells infected with the LV-G4-H10 are successfully obtained (G4-H10-MSC).
The obtained G4-H10-MSC and hUC-MSC cells were cultured to a T25 cell culture flask according to 1X 10 4/cm 2, after the cell density reached 80-90%, a transport inhibitor (purchased from BD Co., U.S.A., accession number 555029) was added, and after fixation, washing and staining of FITC-Protein A (stained FITC-Protein A, purchased from BOSTER Boschia, accession number BA 1120), the mesenchymal stem cells were subjected to FITC channel signaling (see FIG. 7 for results), and the G4-H10-MSC cells were found to have a positive rate of more than 60% in the FITC channel signaling, whereas normal mesenchymal stem cells (hUC-MSC) had no signaling in the FITC channel, indicating that LV-G4-H10:Fc lentivirus can successfully infect mesenchymal stem cells, the infection rate was nearly 70%.
EXAMPLE 3ELISA method for detecting the expression of IgG4 and IL-17Nb in G4-H10-MSC cells
G4-H10-MSC and hUC-MSC obtained in example 2 were cultured in a T25 cell culture flask according to 1X 10 4 cells/cm 2, and after 72 hours of culture, the cell supernatants were harvested and frozen in aliquots for detection of IgG4, IL-17Nb antibody content and blocking efficiency.
1. ELISA method for detecting the expression of IgG4 in G4-H10-MSC cell prepared in example 2
Human IgG4 ELISA Kit (Human IgG4 ELISA Kit, available from Thermosameimer, cat# BMS 2095) from Invitrogen corporation (England Life technologies Co., ltd.) was used to measure the amount of secreted fusion protein IgG4 in the cell culture supernatant. The kit adopts a human IgG4 solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) to detect the amount of the target bound between the matched antibody pair. IgG 4-specific antibodies have been pre-coated in an elisa plate, and then cell supernatant samples, standards or controls are added to these wells and bound to immobilized (capture) antibodies, forming a sandwich structure by adding secondary antibodies, and the added substrate solution is reacted with the enzyme-antibody-target complex to produce a measurable signal. The intensity of the signal is proportional to the target concentration present in the original sample.
The cell culture supernatant prepared in this example was subjected to the above-mentioned human IgG4 ELISA kit to detect the content of IgG4 protein in the fusion protein, and as a result, it was found that G4-H10-MSC (detected after 25-fold dilution) highly expressed IgG4 up to 10.43.+ -. 0.52. Mu.g/mL, whereas normal hUC-MSC did not express IgG4 (see FIG. 8 for the results).
2. IL-17Nb antibody content detection
IL-17A nanobody expression was detected by IL-17A protein binding assay, and the cell supernatants obtained in this example were examined (20-fold best dilution was found after various-fold dilutions were made) after blocking with BSA by coating the ELISA plate with IL-17A protein (prepared in basic Experimental example 1) at a final concentration of 2. Mu.g/mL at 4℃overnight. Standard is G4-H10 fusion Protein (target antibody Protein prepared in basic experimental example 2), standard is added to corresponding wells at concentration ranging from 0-250ng/mL, sample wells are added to hUC-MSC and G4-H10-MSC cell supernatant (20-fold dilution) and incubated for 1H, HRP-labeled Protein a antibody (purchased from doctor, cat No. BA 1080) is then used as an enzyme-labeled antibody for 1H, TMB is finally added to develop color for 20min in the dark, and the enzyme-labeled instrument detects OD450nm values of each well after termination. As shown in FIG. 9, the high expression of IL-17Nb by G4-H10-MSC can be determined by the IL-17A binding experiment, the concentration is 4106+/-185.84 ng/mL, which shows that the IL-17Nb expressed by G4-H10-MSC can bind with IL-17A, while the IL-17Nb is not expressed by normal mesenchymal stem cells hUC-MSC.
EXAMPLE 4ELISA determination of IL-17Nb ability to block IL-17A binding to IL-17RA
IL-17A [ biotinylated ] IL-17RA Inhibitor Screening ELISA Kit (IL-17A/IL-17 RA blocking kit, cat. EP-139) from the company ACRO Biosystems (Baipasis) was used to examine the ability of G4-H10-MSC cells to block IL-17A/IL-17RA binding. The kit coats IL-17RA, takes a neutralizing antibody of anti-IL-17A as a standard substance, blocks the combination of the IL-17RA and biotinylated IL-17A, judges the blocking capacity by detecting the OD450nm value, and has the inverse relation between the blocking capacity and the OD450nm value, wherein the stronger the blocking capacity of the IL-17A/IL17RA is, the lower the OD450nm value is. After the supernatant obtained in example 3 was subjected to a certain dilution (dilution of 5-fold was found to be optimal), the ability of IL-17Nb to block IL-17A/IL17RA binding in the supernatant was examined by an IL-17A/IL17RA blocking kit.
IL-17A/IL17RA binding inhibition was calculated using the following formula:
binding inhibition (%) = [ OD450 (positive well) -OD450 (sample well) ]/OD450 (positive well) ×100%.
All samples were tested after 5-fold dilution according to the instructions, as shown in FIG. 10, normal hUC-MSC cells could not block IL-17A/IL17RA binding, whereas G4-H10-MSC cells secreted IL-17Nb could block IL-17A/IL17RA binding, with a 5-fold inhibition as high as 60%.
EXAMPLE 5 Stem cell stability Studies
IL-17Nb expression was examined by ELISA, the obtained IL-17 Nb-modified mesenchymal stem cells G4-H10-MSC and control hUC-MSC were inoculated in 24-well plates at 1X 10 4/cm 2, 8-well and 16-well plates were inoculated, respectively, after overnight culture, 8-well hUC-MSCs were randomly selected to replace complete medium containing the G4-H10 fusion protein (the target antibody protein prepared in basic Experimental example 2) at a final concentration of 2000ng/mL, culture was continued, supernatants were harvested at 24H, 48H, 72H and 96H, respectively, and the IL17Nb content in the supernatant was examined by the method of example 3 (ELISA method for detecting IL17Nb expression). As a result, as shown in FIG. 11, the IL17Nb content measured in the hUC-MSC-added G4-H10 group was reduced from 1986.+ -. 79.90ng/mL to 1620.+ -. 37.54ng/mL over time, the concentration was gradually decreased, and the IL17Nb expressed by the IL17Nb-MSC (G4-H10-MSC) was increased from 1333.+ -. 334.79 for 24 hours to 5554.+ -. 508.12ng/mL for 96 hours over time, and there was a very significant difference (P < 0.001) between the two groups of hUC-MSC-added G4-H10 and G4-H10-MSC over 72 hours and 96 hours. The result shows that the G4-H10-MSC can stably and continuously express and secrete IL-17Nb, and the expression concentration and stability are better than those of the recombinant G4-H10 protein.
Example 6 validation of treatment efficacy in mice inflammatory disease models
This example uses the psoriatic arthritis (PsA) model for efficacy verification.
A model of psoriatic arthritis (PsA) was constructed by intraperitoneal injection of mannan in B-hIL17A transgenic mice (Bai Chart pharmaceutical technologies Co., ltd., cat No. 110053). Taking a model mouse, performing three times of intraperitoneal injections of mannans at D0, D4 and D8 respectively when the first intraperitoneal injection is marked as D0. The molding was performed by three intraperitoneal injections of mannan (SIGMA, SIGMA, M7504-5G) at a volume of 200. Mu.L per animal per 100mg/mL of mannan per abdominal cavity, i.e., 20mg of mannan per animal per abdominal cavity.
The PsA model group was randomly divided into four groups: hUC-MSC treated group (2X 10 6 /), positive antibody Ixekizumab treated group (1 mg/kg body weight), G4-H10-MSC treated group (2X 10 6 /) and model control group;
Drug treatment groups were D3 and D7 intravenous administration treatments. During the experiment, animal body weight was measured every 2 days, animal survival and health were observed, and animal skin and fore-and-aft paw were scored according to relevant indicators. D14 euthanized animals, peripheral blood from mice was collected, serum was isolated, and cytokines such as mIL-6, mIL-23, mTNF- α, etc., were detected (kit brands were all Biolegend).
Skin clinical scoring criteria: scoring animal skin (ear, front and rear paws), comprehensively scoring according to erythema, scales and thickness, wherein each index score is divided into 5 grades and 0-5 grades, wherein 0 represents no related symptoms; score 1 represents mild symptoms; score 2 indicates symptoms are general; score 3 indicates significant symptoms; score 4 indicates very significant or severe and a total score of 3 indicators was calculated as the final score.
Paw (joint) scoring criteria were as follows: 0 = normal; 1 = single finger erythema and swelling in the paw; 2 = erythema and swelling of two fingers in the paw; 3 = more than two digits erythema and swelling in the paw and/or ankle swelling. The total score of 4 paws was calculated as the final score.
As shown in fig. 12, the body weight of the PsA model group after the mannan modeling was significantly reduced compared with the normal control group, the hUC-MSC treated group and the G4-H10-MSC treated group both restored the body weight of the mice, while the positive antibody group restored the body weight of the mice less significantly, and the test endpoint G4-H10-MSC treated group had significantly higher body weight than the positive antibody group.
As shown in fig. 13-14, the clinical scores of animal paw and skin were significantly increased in both the PsA model group and paw after mannan modeling, and positive antibody, hic-MSC treatment and G4-H10-MSC treatment groups significantly reduced the clinical scores of the paw and skin in the model animals, while the weight of the G4-H10-MSC treated mice was significantly better than that of the positive antibody group.
The inflammatory factor detection results are shown in fig. 15-17, and the serum of the PsA model animal is obviously increased in cytokines such as IL-6, IL-23 and TNF-alpha after the mannan modeling, while the serum IL-6 and TNF-alpha levels of the model animal can be obviously reduced in both the hUC-MSC treatment and the G4-H10-MSC treatment, and the serum IL-23 level of the model animal can be obviously reduced in both the positive antibody group and the G4-H10-MSC treatment.
Finally, it should be noted that the above description is only for illustrating the technical solution of the present invention, and not for limiting the scope of the present invention, and that the simple modification and equivalent substitution of the technical solution of the present invention can be made by those skilled in the art without departing from the spirit and scope of the technical solution of the present invention.
Claims (13)
1. A stem cell modified based on a nanobody gene, which is characterized by comprising, expressing or secreting a first antibody and a second antibody specifically recognizing IL-17A, wherein the first antibody comprises HCDR1, HCDR2 and HCDR3 with sequences shown in SEQ ID NO. 1-3; the second antibody comprises HCDR4, HCDR5 and HCDR6 with sequences shown in SEQ ID NO. 4-6; the first antibody and the second antibody are connected through a connector, and the connector is an amino acid sequence shown as SEQ ID NO. 15; the stem cells are mesenchymal stem cells.
2. The stem cell of claim 1, wherein the structure of the first antibody comprises: FR1-HCDR1-FR2-HCDR2-FR3-HCDR3-FR4;
The structure of the second antibody comprises: FR5-HCDR4-FR6-HCDR5-FR7-HCDR6-FR8;
Wherein the sequence of FR1-FR8 is the amino acid sequence shown in SEQ ID NO. 7-14.
3. The stem cell of claim 2, wherein the sequence of the first antibody comprises the amino acid sequence shown in SEQ ID No. 16; the sequence of the second antibody comprises an amino acid sequence shown as SEQ ID NO. 17.
4. A stem cell according to claim 3, comprising, expressing and/or secreting a fusion protein having the sequence of amino acids indicated by SEQ ID No. 16-SEQ ID No. 15-SEQ ID No. 17-SEQ ID No. 26.
5. The stem cell of claim 1, comprising: a nucleic acid molecule 1 encoding a first antibody and a nucleic acid molecule 2 encoding a second antibody.
6. The stem cell of claim 5, wherein the nucleic acid molecule 1 and the nucleic acid molecule 2 are linked by a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO. 15.
7. The stem cell of claim 6, wherein the nucleic acid molecule 1 encodes the nucleotide sequence of the amino acid sequence shown in SEQ ID NO. 16; the nucleic acid molecule 2 codes for the nucleotide sequence of the amino acid sequence shown in SEQ ID NO. 17.
8. The stem cell of claim 7, comprising a nucleic acid molecule 3, wherein said nucleic acid molecule 3 encodes a nucleotide sequence of the amino acid sequence represented by SEQ ID NO. 16-SEQ ID NO. 15-SEQ ID NO. 17-SEQ ID NO. 26.
9. Cell culture, characterized in that it is obtained by culturing stem cells according to any one of claims 1 to 8.
10. A pharmaceutical composition, characterized in that it comprises a stem cell according to any one of claims 1-8 or a cell culture according to claim 9.
11. Kit, characterized in that it comprises a stem cell according to any one of claims 1 to 8 or a cell culture according to claim 9.
12. A method of preparing a stem cell according to any one of claims 1 to 8, comprising: introducing the nucleic acid molecule into the stem cell by viral transfection, liposome transfection, electrotransfer, gene editing or mRNA transfection; the nucleic acid molecules comprise a nucleic acid molecule 1 encoding a first antibody and a nucleic acid molecule 2 encoding a second antibody.
13. A method for in vitro detection of IL-17A in a sample for non-diagnostic purposes, characterized in that the method comprises the steps of:
D1: contacting the stem cell of any one of claims 1-8 or the cell culture of claim 9 with a test sample;
d2: detecting the antigen-antibody complex;
D3: and judging the result.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410276793.3A CN117866905B (en) | 2024-03-12 | 2024-03-12 | Stem cell based on nanobody gene modification and preparation method and product thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410276793.3A CN117866905B (en) | 2024-03-12 | 2024-03-12 | Stem cell based on nanobody gene modification and preparation method and product thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117866905A CN117866905A (en) | 2024-04-12 |
CN117866905B true CN117866905B (en) | 2024-06-04 |
Family
ID=90595351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410276793.3A Active CN117866905B (en) | 2024-03-12 | 2024-03-12 | Stem cell based on nanobody gene modification and preparation method and product thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117866905B (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013216585A1 (en) * | 2006-11-29 | 2013-08-29 | Genentech, Inc. | IL-17A/F heterodimeric polypeptides and therapeutic uses thereof |
CN103717618A (en) * | 2011-05-05 | 2014-04-09 | 默克专利股份有限公司 | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
CN105079792A (en) * | 2014-05-14 | 2015-11-25 | 中国科学院上海生命科学研究院 | Application of IL-17 in improving mesenchymal stem cell immunity inhibition function |
CN109679920A (en) * | 2018-12-26 | 2019-04-26 | 北京贝来生物科技有限公司 | A kind of mescenchymal stem cell for expressing IL-17A signal path blocking agent |
CN117820478A (en) * | 2023-12-29 | 2024-04-05 | 北京贝来药业有限公司 | Tandem molecules of nanobodies and their use in the treatment of diseases |
CN117820479A (en) * | 2023-12-29 | 2024-04-05 | 北京贝来药业有限公司 | Novel nanobody against IL-17A |
CN117866904A (en) * | 2024-03-12 | 2024-04-12 | 北京贝来药业有限公司 | Pharmaceutical use of stem cells based on single domain antibody gene modification for various diseases |
-
2024
- 2024-03-12 CN CN202410276793.3A patent/CN117866905B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013216585A1 (en) * | 2006-11-29 | 2013-08-29 | Genentech, Inc. | IL-17A/F heterodimeric polypeptides and therapeutic uses thereof |
CN103717618A (en) * | 2011-05-05 | 2014-04-09 | 默克专利股份有限公司 | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
CN105079792A (en) * | 2014-05-14 | 2015-11-25 | 中国科学院上海生命科学研究院 | Application of IL-17 in improving mesenchymal stem cell immunity inhibition function |
CN109679920A (en) * | 2018-12-26 | 2019-04-26 | 北京贝来生物科技有限公司 | A kind of mescenchymal stem cell for expressing IL-17A signal path blocking agent |
CN117820478A (en) * | 2023-12-29 | 2024-04-05 | 北京贝来药业有限公司 | Tandem molecules of nanobodies and their use in the treatment of diseases |
CN117820479A (en) * | 2023-12-29 | 2024-04-05 | 北京贝来药业有限公司 | Novel nanobody against IL-17A |
CN117866904A (en) * | 2024-03-12 | 2024-04-12 | 北京贝来药业有限公司 | Pharmaceutical use of stem cells based on single domain antibody gene modification for various diseases |
Non-Patent Citations (2)
Title |
---|
IL-17A contributes to propagation of inflammation but does not impair adipogenesis and/or insulin response, in adipose tissue of obese individuals;Julien Pestel等;《Cytokine》;20191016;第126卷(第154965期);第1-9页 * |
人噬菌体抗体库的构建及人源性IL-17单链抗体的筛选;钮敏红等;《中国临床研究》;20160520;第29卷(第5期);第687-691页 * |
Also Published As
Publication number | Publication date |
---|---|
CN117866905A (en) | 2024-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2749451T3 (en) | Binding molecules for BCMA and CD3 | |
US20160289322A1 (en) | Human anti-il-33 neutralizing monoclonal antibody | |
WO2018233574A1 (en) | Anti-pd-l1 humanized nanobody and use thereof | |
JP2019525730A (en) | Anti-human interleukin-17A monoclonal antibody, production method and use thereof | |
JP2021502407A (en) | 4-1BB antibody and its production method and use | |
TW201010725A (en) | Anti-IL-12/IL-23 antibodies | |
CN111269315B (en) | Monoclonal antibodies against BCMA | |
CN117866904B (en) | Pharmaceutical use of stem cells based on single domain antibody gene modification for various diseases | |
CN117860786B (en) | Pharmaceutical and diagnostic use of genetically modified mesenchymal stem cells in a variety of diseases | |
JP2022521937A (en) | Antibody molecules that bind to NKp30 and their use | |
CN117866903B (en) | Single domain antibody modified stem cells and their use in the treatment of disease | |
EP4101867A1 (en) | Anti-cd3 and anti-cd123 bispecific antibody and use thereof | |
CN111454358A (en) | Chimeric antigen receptor and application thereof | |
WO2020199860A1 (en) | Binder against programmed death-ligand and application thereof | |
JP2022521428A (en) | Methods and compositions for treating inflammatory and autoimmune conditions with ECM-affinity peptides linked to anti-inflammatory agents. | |
CN117843803A (en) | Novel tandem single domain antibodies and their use in the treatment of disease | |
CN117820478A (en) | Tandem molecules of nanobodies and their use in the treatment of diseases | |
CN117820479A (en) | Novel nanobody against IL-17A | |
WO2015113494A1 (en) | Bifunctional fusion protein, preparation method therefor, and use thereof | |
CN117866905B (en) | Stem cell based on nanobody gene modification and preparation method and product thereof | |
CN116323671A (en) | Multi-targeting bispecific antigen binding molecules with increased selectivity | |
KR102598319B1 (en) | Anti-IL-25 antibodies and uses thereof | |
WO2024125445A1 (en) | BISPECIFIC FUSION PROTEIN TARGETING TNF-α AND IL-17A, AND USE THEREOF | |
WO2024140816A1 (en) | Anti-cd33/cll1 bispecific antibody-natural killer cell conjugate and use thereof | |
CN114591432B (en) | anti-TNFalpha single domain antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |